Claims of equivalence in medical research: are they supported by the evidence?

PubWeight™: 2.27‹?› | Rank: Top 2%

🔗 View Article (PMID 10787365)

Published in Ann Intern Med on May 02, 2000

Authors

W L Greene1, J Concato, A R Feinstein

Author Affiliations

1: Yale University School of Medicine, New Haven, Connecticut, USA. wgreene@gene.com

Articles citing this

Absence of evidence is not evidence of absence. BMJ (2004) 2.06

St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician (2002) 1.46

How well is the clinical importance of study results reported? An assessment of randomized controlled trials. CMAJ (2001) 1.31

Noninferiority and equivalence designs: issues and implications for mental health research. J Trauma Stress (2008) 1.20

Survey of claims of no effect in abstracts of Cochrane reviews. BMJ (2003) 1.14

Do all psychological treatments really work the same in posttraumatic stress disorder? Clin Psychol Rev (2009) 0.98

Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III). Curr Control Trials Cardiovasc Med (2004) 0.90

Rationale for and methods of superiority, noninferiority, or equivalence designs in orthopaedic, controlled trials. Clin Orthop Relat Res (2011) 0.86

Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature. Trials (2008) 0.81

Comparative study of control selection in a national population-based case-control study: Estimating risk of smoking on cancer deaths in Chinese men. Int J Med Sci (2009) 0.81

Interval exercise versus continuous exercise in patients with moderate to severe chronic obstructive pulmonary disease--study protocol for a randomised controlled trial [ISRCTN11611768]. BMC Pulm Med (2004) 0.80

Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris. Trials (2010) 0.79

Low dosage tricyclic antidepressants in depression. Giving low dose tricyclics is not justified by evidence. BMJ (2003) 0.75

Choice of non-inferiority (NI) margins does not protect against degradation of treatment effects on an average--an observational study of registered and published NI trials. PLoS One (2014) 0.75

What's new in trial design: propensity scores, equivalence, and non-inferiority. J Extra Corpor Technol (2009) 0.75

An evaluation of class effect. CMAJ (2006) 0.75

While modern medicine evolves continuously, evidence-based research methodology remains: how register studies should be interpreted and appreciated. Knee Surg Sports Traumatol Arthrosc (2017) 0.75

Articles by these authors

A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol (1996) 20.25

Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med (1978) 11.42

A critical appraisal of the quality of quality-of-life measurements. JAMA (1994) 9.10

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med (1985) 8.55

High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol (1990) 8.28

Clinical biostatistics. LIV. The biostatistics of concordance. Clin Pharmacol Ther (1981) 7.33

Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol (1995) 6.94

The risk of determining risk with multivariable models. Ann Intern Med (1993) 6.45

Variability in radiologists' interpretations of mammograms. N Engl J Med (1994) 5.96

Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA (1995) 5.94

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19

Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int (2007) 4.74

Importance of functional measures in predicting mortality among older hospitalized patients. JAMA (1998) 4.33

Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med (1992) 3.64

Academic calculations versus clinical judgments: practicing physicians' use of quantitative measures of test accuracy. Am J Med (1998) 3.36

Problems of comorbidity in mortality after prostatectomy. JAMA (1992) 3.27

Clinical epidemiological quality in molecular genetic research: the need for methodological standards. JAMA (1999) 3.07

An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA (1979) 3.03

The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis (1974) 3.01

The BCG controversy. A methodological and statistical reappraisal. JAMA (1983) 2.60

Clinical biostatistics. XXXVII. Demeaned errors, confidence games, nonplussed minuses, inefficient coefficients, and other statistical disruptions of scientific communication. Clin Pharmacol Ther (1976) 2.53

An analysis of diagnostic reasoning. 3. The construction of clinical algorithms. Yale J Biol Med (1974) 2.44

Context bias. A problem in diagnostic radiology. JAMA (1996) 2.42

Scientific and clinical problems in indexes of functional disability. Ann Intern Med (1986) 2.41

The qualification period. J Clin Epidemiol (1991) 2.33

Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol (1995) 2.32

A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med (1990) 2.32

Clinical biostatistics. 8. An analytic appraisal of the University Group Diabetes Program (UGDP) study. Clin Pharmacol Ther (1971) 2.28

Coding ordinal independent variables in multiple regression analyses. Am J Epidemiol (1987) 2.15

A new prognostic staging system for the acquired immunodeficiency syndrome. N Engl J Med (1989) 2.10

Methodologic standards and contradictory results in case-control research. Am J Med (1979) 2.09

Clinical biostatistics. XLIV. A survey of the research architecture used for publications in general medical journals. Clin Pharmacol Ther (1978) 2.07

T. Duckett Jones Memorial Lecture. The Jones criteria and the challenges of clinimetrics. Circulation (1982) 2.06

Clinical biostatistics. XLI. Hard science, soft data, and the challenges of choosing clinical variables in research. Clin Pharmacol Ther (1977) 2.04

A collection of 56 topics with contradictory results in case-control research. Int J Epidemiol (1988) 2.02

The impact of ethnicity, family income, and parental education on children's health and use of health services. Am J Public Health (1999) 2.02

A new clinical prognostic staging system for acute pancreatitis. Am J Med (1993) 2.02

The 'chagrin factor' and qualitative decision analysis. Arch Intern Med (1985) 1.94

Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet (1979) 1.92

An additional basic science for clinical medicine: II. The limitations of randomized trials. Ann Intern Med (1983) 1.87

Clinical biostatistics. XXV. A survey of the statistical procedures in general medical journals. Clin Pharmacol Ther (1974) 1.87

Double standards, scientific methods, and epidemiologic research. N Engl J Med (1982) 1.81

Clinical biostatistics. XXXIX. The haze of Bayes, the aerial palaces of decision analysis, and the computerized Ouija board. Clin Pharmacol Ther (1977) 1.80

An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity. JAMA (1979) 1.65

Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol (1990) 1.63

Measurement of lower limb alignment using long radiographs. J Bone Joint Surg Br (1991) 1.58

Current problems and future challenges in randomized clinical trials. Circulation (1984) 1.57

An analysis of Berkson's bias in case-control studies. J Chronic Dis (1986) 1.53

Clinical biostatistics XXXI. On the sensitivity, specificity, and discrimination of diagnostic tests. Clin Pharmacol Ther (1975) 1.52

Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis (1970) 1.51

Complications of peripheral arteriography: a new system to identify patients at increased risk. J Vasc Surg (1995) 1.50

The problems of the "problem-oriented medical record". Ann Intern Med (1973) 1.50

Clinical biostatistics. XX. The epidemiologic trohoc, the ablative risk ratio, and "retrospective" research. Clin Pharmacol Ther (1973) 1.50

The role of diagnostic inconsistency in changing rates of occurrence for coronary heart disease. J Clin Epidemiol (1992) 1.50

On white-coat effects and the electronic monitoring of compliance. Arch Intern Med (1990) 1.48

Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis (2004) 1.47

Joseph Goldberger: an unsung hero of American clinical epidemiology. Ann Intern Med (1994) 1.47

A bibliography of publications on observer variability (final installment). J Clin Epidemiol (1992) 1.47

An analysis of diagnostic reasoning. I. The domains and disorders of clinical macrobiology. Yale J Biol Med (1973) 1.47

Clinical utility of endoscopic retrograde cholangiopancreatography. Gastrointest Endosc (1997) 1.45

Risk adjustment for older hospitalized persons: a comparison of two methods of data collection for the Charlson index. J Clin Epidemiol (2001) 1.44

Bootstraps and jackknives: new, computer-intensive statistical tools that require no mathematical theories. J Investig Med (1998) 1.43

An additional basic science for clinical medicine: IV. The development of clinimetrics. Ann Intern Med (1983) 1.43

Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med (2000) 1.42

Discontinuation of antistreptococcal prophylaxis. A double-blind study in rheumatic patients free of heart disease. JAMA (1966) 1.42

A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction. N Engl J Med (1969) 1.42

The problem of "protopathic bias" in case-control studies. Am J Med (1980) 1.41

Comparison of dermatologic diagnoses by primary care practitioners and dermatologists. A review of the literature. Arch Fam Med (1999) 1.39

On exorcizing the ghost of Gauss and the curse of Kelvin. MD Comput (1992) 1.39

Coffee and pancreatic cancer. The problems of etiologic science and epidemiologic case-control research. JAMA (1981) 1.37

Clinical biostatistics. XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size. Clin Pharmacol Ther (1975) 1.36

The 'epidemiologic necropsy'. Unexpected detections, demographic selections, and changing rates of lung cancer. JAMA (1987) 1.35

Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis (1979) 1.34

New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. JAMA (1989) 1.34

Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer (1996) 1.31

Boning up on estrogen: new options, new concerns. JAMA (1996) 1.30

An additional basic science for clinical medicine: I. The constraining fundamental paradigms. Ann Intern Med (1983) 1.29

Informed consent for PSA screening: does it happen? Eff Clin Pract (1999) 1.28

Clinical effects of recurrent attacks of acute rheumatic fever: a prospective epidemiologic study of 105 episodes. J Chronic Dis (1967) 1.28

Monte Carlo methods in clinical research: applications in multivariable analysis. J Investig Med (1997) 1.28

Operational criteria for adverse drug reactions in evaluating suspected toxicity of a popular scabicide. Clin Pharmacol Ther (1980) 1.27

Clinical biostatistics. XXVII. The derangements of the 'range of normal'. Clin Pharmacol Ther (1974) 1.27

Clinical biostatistics. II. Statistics versus science in design of experiments. Clin Pharmacol Ther (1970) 1.27

Clinical biostatistics. 28. The biostatistical problems of pharmaceutical surveillance. Clin Pharmacol Ther (1974) 1.26

What kind of basic science for clinical medicine? N Engl J Med (1970) 1.25

Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med (1978) 1.25

Ask patients what they want. Evaluation of individual complaints before total hip replacement. J Bone Joint Surg Br (1994) 1.23

Invidious comparisons and unmet clinical challenges. Am J Med (1992) 1.22

The need for humanised science in evaluating medication. Lancet (1972) 1.21

Necropsy evidence of detection bias in the diagnosis of lung cancer. Arch Intern Med (1986) 1.21

Symptoms as an index of biological behaviour and prognosis in human cancer. Nature (1966) 1.20

Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am J Cardiol (1990) 1.20

The role of tonsils in predisposing to streptococcal infections and recurrences of rheumatic fever. N Engl J Med (1970) 1.17

The impact of clinical history on mammographic interpretations. JAMA (1997) 1.17

A bibliography of publications on observer variability. J Chronic Dis (1985) 1.17

The auxometric dimension. A new method for using rate of growth in prognostic staging of breast cancer. JAMA (1974) 1.17

A reappraisal of histopathology in lung cancer and correlation of cell types with antecedent cigarette smoking. Am Rev Respir Dis (1973) 1.17